Immunocore Holdings (IMCR) Change in Account Payables (2023 - 2026)

Immunocore Holdings has disclosed Change in Account Payables across 4 years of filings, most recently posting $6.0 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $6.0 million, up 78.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $176000.0 (down 98.64% YoY), and the FY2025 annual result was -$2.5 million, down 133.77% from the prior year.
• Change in Account Payables came in at $6.0 million for Q1 2026 at Immunocore Holdings, up from $1.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.0 million in Q2 2023 to a low of -$6.9 million in Q2 2025.
• The 4-year median for Change in Account Payables is $1.4 million (2025), against an average of $1.0 million.
• Peak annual rise in Change in Account Payables reached 244.05% in 2025, while the deepest fall reached 254.53% in 2025.
• Immunocore Holdings' Change in Account Payables stood at $3.8 million in 2023, then soared by 56.7% to $5.9 million in 2024, then tumbled by 75.9% to $1.4 million in 2025, then soared by 321.3% to $6.0 million in 2026.
• The last three Change in Account Payables figures came in at $6.0 million (Q1 2026), $1.4 million (Q4 2025), and -$287000.0 (Q3 2025), per Business Quant data.